Our findings suggest that there is a level of epigenetic heterogeneity within these cancers, and it could also be beneficial to investigate the use of Sirtuins (SIRT1-7), a class of deacetylases selectively targeting H3K18, as another potential therapeutic option at least in selected cases75. This evidence concerns the gene SIRT1 and cancer.